Kadcyla 100 mg powder for concentrate for solution for infusion.
Sponsors
Daiichi Sankyo Inc., Karolinska University Hospital, Rigshospitalet, BOOG Study Center B.V.
Conditions
Breast cancerCancerHigh-Risk HER2-Positive Breast CancerMetastatic breast cancerPrimary breast cancer
Phase 2
PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive
breast cancer. Part of a platform of translational phase II trials based on
molecular subtypes
Active, not recruitingCTIS2023-508411-23-00
Start: 2014-11-12Target: 200Updated: 2025-11-17
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling
RecruitingCTIS2023-510527-29-00
Start: 2020-09-01Target: 600Updated: 2025-04-25
Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study
Active, not recruitingCTIS2024-516205-23-00
Start: 2019-04-09Target: 472Updated: 2024-11-12
Phase 3
A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03)
Active, not recruitingCTIS2024-511204-16-00
Start: 2019-01-23Target: 63Updated: 2025-06-27
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
Active, not recruitingCTIS2023-507961-24-00
Start: 2021-04-19Target: 1124Updated: 2026-01-26